Dataset opportunity
Histosonics — Medical Imaging Dataset Opportunity
Large medical imaging dataset held by Histosonics, usable for Diagnostic AI and Computer Vision.
Score
81.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
92%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in medical diagnostics market = $1.64 billion in 2023, CAGR 26.40% (source: BlueWeave Consulting)
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-10
Medicaroid wins Europe’s CE mark for Hinotori surgical robot
medtechdive.com ↗ - 📰press2026-07-09
ForSight Robotics’ road to performing a fully robotic cataract surgery
therobotreport.com ↗ - 📰press2026-07-09
Stereotaxis closes Robocath takeover
medtechdive.com ↗ - 📰press2026-07-09
4 takeaways from MDUFA VI draft agreement
medtechdive.com ↗ - 📰press2026-07-09
J&J wins FDA approval for dual-energy ablation catheter
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Large
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Histosonics possesses a unique Medical Imaging Dataset composed of proprietary ultrasound imaging and treatment telemetry, which is deeply integrated with `medical_records` and data from `clinical trial` protocols. This rich, multi-modal collection provides the high-quality, curated evidence necessary for developing and validating robust Diagnostic AI algorithms, particularly for novel treatment applications.
The global AI in medical diagnostics market was valued at USD 1.64 billion in 2023 and is projected to grow at a remarkable CAGR of 26.40%. [5] While access is complex due to highly sensitive patient information (PHI) and its nature as core intellectual property tied to regulatory filings, the dataset's rarity and direct applicability make it a strategic asset for capturing share in this high-growth market. ⚠ Diligence (valuable data, access to negotiate): Highly sensitive medical and patient health information (PHI) subject to HIPAA/GDPR.; Data is tied to clinical trial protocols and regulatory filings.; Proprietary ultrasound imaging and treatment telemetry are core IP. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Histosonics possesses a proprietary dataset of medical images from its clinical trials for a novel, non-invasive cancer therapy. This is a high-value asset for training diagnostic AI models in the rapidly growing medical diagnostics market, which is expanding at over 26% annually. The dataset uniquely links radiology images of liver tumors to specific patient outcomes and device parameters from the company's FDA-authorized histotripsy platform, offering a rare opportunity to build and validate next-generation AI tools.
See dimension details ↓- Dataset Specificity100
dominant 'medical_records', sector healthcare, 4 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume100
15 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value94
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is exceptionally high, driven by the need for proprietary, clinically-validated imaging data to compete in the AI in medical diagnostics market, which is expanding at a 26.40% CAGR. [5]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility26
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility50
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength100
7 evidence types, 15 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Histosonics is a medical device company whose core business is selling the Edison System, a machine that uses focused ultrasound for non-invasive tumor destruction; the imaging and procedural data generated is a by-product of its operational use, not its primary product. Issues: The company has between 200-418 employees, placing it on the larger end of the SME scale. [3, 4, 8, 12]; It is very well-funded (over $300M raised) and recently had a majority stake acquisition, indicating it is a mature, high-growth company rather than a small, un
- Deep Qualification90
⚠ needs review — HistoSonics is a medical device company whose core business is selling the Edison Histotripsy System, not data. The ultrasound imaging and clinical data generated are a highly restricted byproduct of its device's operation and clinical trials, with ownership shared between HistoSonics (as the sponsor) and the clinical sites/investigators. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
These documents represent a portfolio of formal clinical research, providing structured bibliographies and trial information that establish the scientific and regulatory provenance of the imaging data.
Medical records / imaging
This is direct evidence of a core clinical imaging dataset, including radiology images from pivotal trials with documented patient cohorts and outcomes—the essential ground truth for training diagnostic models.
Court documents
This text confirms the existence of formal training protocols, indicating that the resulting data is generated under standardized procedures which enhances its reliability for AI model training.
API access
This multimodal evidence points to structured clinical trial results accessible programmatically, offering quantifiable success metrics that can be used to label and validate the associated imaging data at scale.
Developer portal
Public announcements of financing and strategic investment confirm the company's ongoing commercialization efforts, ensuring the dataset is tied to a viable, market-relevant medical device.
Image collection
This content provides technical metadata explaining the unique visual artifacts of the histotripsy process, which is crucial context for an AI to correctly interpret the imaging features.
IoT / sensor data
This time-series evidence indicates the system generates device telemetry, offering a path to a rich, multimodal dataset that correlates machine performance parameters with imaging results and clinical outcomes.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Histosonics Medical Imaging — a Large medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in medical diagnostics market = $1.64 billion in 2023, CAGR 26.40% (source: BlueWeave Consulting). Investment score 81.6/100 (confidence 0.92). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Docobo — Medical Imaging Dataset Opportunity
View opportunity →healthcareFilab — Industrial Operations Dataset Opportunity
View opportunity →healthcareSniclinic — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Acquire Rare, Compliant Data3 min read
- Is Your Data Worth Money?3 min read
- What is a Dataset Worth?3 min read